Zollner’s Scleritis

What is Zollner’s Scleritis?

Zollner’s scleritis is a rare, chronic, inflammatory disease of the sclera (the white, protective outer layer of the eye). It is named after the German ophthalmologist Dr. Hugo Zollner, who first described the condition in the early 20th century. Unlike the more common anterior scleritis that causes deep, aching pain, Zollner’s scleritis typically presents as a localized, nodular thickening of the posterior sclera that may be discovered incidentally on imaging or during an eye‑examination for other problems. The inflammation can be diffuse or focal and may lead to scleral thinning, uveal (choroidal) involvement, and, in severe cases, vision‑threatening complications.

The exact pathophysiology is not fully understood, but immune‑mediated mechanisms—often associated with systemic autoimmune disease—play a central role. Because the condition is uncommon, many clinicians may not recognize it immediately, making patient education and timely referral essential.

Common Causes

The inflammation seen in Zollner’s scleritis is usually secondary to an underlying systemic or ocular condition. The most frequently reported associations include:

• Rheumatoid arthritis – the leading systemic autoimmune cause of scleritis.
• Granulomatosetive polyangiitis (GPA, formerly Wegener’s) – small‑vessel vasculitis that can involve the eye.
• Sjögren’s syndrome – often co‑exists with rheumatoid arthritis and can trigger scleral inflammation.
• Systemic lupus erythematosus (SLE) – produces immune complex deposition in ocular tissues.
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) – extra‑intestinal manifestations may involve the sclera.
• Sarcoidosis – non‑caseating granulomas may affect the posterior sclera.
• Infectious agents – atypical mycobacteria, syphilis, or fungal infections can mimic or precipitate scleritis.
• Uveitis‑associated ocular disease – posterior uveitis may extend to the sclera.
• Idiopathic – in up to 30 % of cases no systemic cause is identified.
• Medication‑related – rare reactions to drugs such as bisphosphonates or anti‑TNF agents.

Associated Symptoms

Because Zollner’s scleritis often involves the posterior segment, patients may not experience the classic severe ocular pain of anterior scleritis. Common accompanying signs and symptoms include:

• Blurry or decreased vision, especially if the macula or optic nerve is affected.
• Feeling of pressure or fullness behind the eye.
• Redness that may be subtle, sometimes limited to a circumferential band.
• Photophobia (light sensitivity).
• Floaters or a “dark spot” if choroidal lesions develop.
• Headache or orbital ache that worsens with eye movement.
• Systemic manifestations of the underlying disease (joint pain, skin rash, respiratory symptoms, etc.).

When to See a Doctor

Early evaluation prevents irreversible damage. Seek ophthalmic care promptly if you notice:

• New or worsening eye redness that does not improve with over‑the‑counter lubricants.
• Pain or a deep ache that intensifies with eye movement.
• Sudden loss of vision, blurry vision, or “shadow” in part of the visual field.
• Photophobia or excessive tearing.
• Any eye symptom associated with a known autoimmune disease flare.

If you belong to a high‑risk group (e.g., diagnosed rheumatoid arthritis) and develop any of the above, schedule an urgent appointment with an ophthalmologist.

Diagnosis

Diagnosing Zollner’s scleritis requires a combination of history taking, clinical examination, and imaging studies.

1. Clinical Examination

• Slit‑lamp biomicroscopy – detects scleral thinning, nodular lesions, and any overlying conjunctival injection.
• Fundoscopy – evaluates posterior segment for choroidal effusions or optic disc changes.
• Tonometry – helps rule out concurrent glaucoma.

2. Imaging

• Ultrasound B‑scan – reveals scleral thickening and helps differentiate from posterior uveal tumors.
• Optical coherence tomography (OCT) – high‑resolution cross‑sectional images of the sclera and choroid.
• Magnetic resonance imaging (MRI) with contrast – evaluates orbital inflammation and excludes orbital cellulitis or neoplasia.

3. Laboratory Work‑up

Because most cases are secondary, targeted tests are performed to uncover systemic disease:

• Complete blood count (CBC) and erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) – markers of inflammation.
• Rheumatoid factor (RF) and anti‑CCP antibodies – screen for rheumatoid arthritis.
• ANCA panel – detects granulomatosis with polyangiitis.
• ANA, dsDNA – evaluate for lupus.
• Serum ACE level – may support sarcoidosis.
• Infectious work‑up (VDRL/RPR, FTA‑ABS, Quantiferon‑TB, fungal serologies) when indicated.

4. Biopsy (rare)

In atypical or refractory cases, a scleral biopsy may be performed to rule out masquerading tumors or infective etiologies.

Treatment Options

Therapy aims to control inflammation, preserve vision, and treat the underlying systemic disease.

1. Systemic Immunosuppression

• Corticosteroids – oral prednisone (initial 0.5–1 mg/kg/day) for rapid control; taper based on response.
• Antimetabolites – methotrexate, azathioprine, or mycophenolate mofetil for steroid‑sparing maintenance.
• Biologic agents –
  • TNF‑α inhibitors (adalimumab, infliximab) especially in rheumatoid arthritis or ulcerative colitis.
  • Rituximab for ANCA‑associated vasculitis.
• Calcineurin inhibitors – cyclosporine or tacrolimus in refractory cases.

2. Local Therapy

• Topical prednisolone acetate 1 % drops (q.i.d.) for milder anterior extension.
• Periocular (sub‑Tenon) injections of triamcinolone for focal lesions when systemic therapy is contraindicated.

3. Adjunctive Measures

• Lubricating eye drops – preservative‑free artificial tears to reduce surface irritation.
• Protective eyewear – shields the eye from wind, dust, and bright light.
• Control of systemic disease (e.g., disease‑modifying antirheumatic drugs for rheumatoid arthritis) is critical for long‑term remission.

4. Monitoring

Regular follow‑up (every 4–6 weeks initially, then spaced out) with repeat imaging ensures that scleral thickness normalizes and that no new complications arise.

Prevention Tips

While you cannot always prevent an autoimmune flare, several strategies can reduce the risk of developing Zollner’s scleritis or its recurrences:

• Adhere to systemic medication regimens for any diagnosed autoimmune disease.
• Maintain routine ophthalmic examinations—at least annually for high‑risk individuals.
• Avoid ocular trauma and protect eyes during sports or hazardous work.
• Quit smoking; tobacco worsens systemic inflammation and impairs ocular healing.
• Manage stress and maintain a healthy diet rich in omega‑3 fatty acids, which have modest anti‑inflammatory effects.
• Promptly treat infections (especially respiratory or sinus infections) that can trigger immune activation.

Emergency Warning Signs

Key Take‑aways

• Zollner’s scleritis is a rare, often posterior, inflammatory condition linked to systemic autoimmune disease.
• Early recognition, comprehensive systemic work‑up, and prompt immunosuppressive therapy are essential to preserve vision.
• Patients with rheumatoid arthritis, GPA, sarcoidosis, or lupus should be especially vigilant for ocular symptoms.
• Regular follow‑up and adherence to systemic treatment dramatically lower the risk of recurrence.

For more detailed information, consult reputable sources such as the Mayo Clinic, the CDC, the NIH, and the Cleveland Clinic. Always discuss any eye symptom or treatment plan with an ophthalmologist or rheumatologist experienced in ocular inflammatory disease.